Biotech stocks came under pressure in the week ended Aug. 14 amid mixed earnings news flow from the sector. FDA decisions scheduled for the week also produced adverse outcomes. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) and Fennec Pharmaceuticals Inc (NASDAQ: FENC) received complete response letters for their respective regulatory applications, while a decision on Eton Pharmaceuticals Inc’s (NASDAQ: ETON) eye inflammation drug hadn’t come by the Aug. 10 decision date.The week, however, saw a signing spree by coronavirus vaccine developers, which stitched up manufacturing as well as supply deals.Here are the key catalysts for the unfolding week.ConferencesVirtual Keystone Symposia: Advances in …read more
Source:: Yahoo Finance
